Henry T. Lynch

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Gene and pathway based burden analyses in familial lymphoid cancer cases: Rare variants in immune pathway genes

  PLoS ONE · 2023-06-28 · 4 citations

• Commentary on This Article from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch SyndromePreprint

  2023-04-03

• Supplementary Methods, Tables 1-3, Figure 1 from Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of <i>BRCA1</i> or <i>BRCA2</i> MutationsPreprint

  2023-04-03

• Supplementary Figure 1 from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch SyndromePreprint

  2023-04-03

• Supplementary Table 1 from Rare Mutations in <i>RINT1</i> Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers

  2023-04-03

• Supplementary Figure Legend from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch SyndromePreprint

  2023-04-03

• Data from Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of <i>BRCA1</i> or <i>BRCA2</i> MutationsPreprint

  2023-04-03

• Related Article from Making Sense of Missense in Lynch Syndrome: The Clinical PerspectivePreprint

  2023-04-03

• Supplementary Table 1 from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome

  2023-04-03

• Supplementary Figure Legend from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch SyndromePreprint

  2023-04-03

• Supplementary Figure 1 from Rare Mutations in <i>RINT1</i> Predispose Carriers to Breast and Lynch Syndrome–Spectrum CancersPreprint

  2023-04-03

• Supplementary Table 2 from Rare Mutations in <i>RINT1</i> Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers

  2023-04-03

• Supplementary Table 3 from Rare Mutations in <i>RINT1</i> Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers

  2023-04-03

• Related Article from Making Sense of Missense in Lynch Syndrome: The Clinical PerspectivePreprint

  2023-04-03

• Data from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch SyndromePreprint

  2023-04-03

• Supplementary Methods, Tables 1-3, Figure 1 from Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of <i>BRCA1</i> or <i>BRCA2</i> MutationsPreprint

  2023-04-03

• Perspective on this Article from Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of <i>BRCA1</i> or <i>BRCA2</i> MutationsPreprint

  2023-04-03

• Perspective on this Article from Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of <i>BRCA1</i> or <i>BRCA2</i> MutationsPreprint

  2023-04-03

• Data from Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of <i>BRCA1</i> or <i>BRCA2</i> MutationsPreprint

  2023-04-03

• Commentary on This Article from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch SyndromePreprint

  2023-04-03